Ultrasensitive Alzheimer's Disease Biomarker Detection with Nanopillar Photonic Crystal Biosensors

The recent development of drugs able to mitigate neurodegenerative diseases has created an urgent need for novel diagnostics. Although biomarker detection directly in patients' blood is now possible, low-cost point-of-care tests remain a challenge, because relevant biomarkers, especially amyloid-β(A$β$) peptides, are small, they occur at very low concentrations, and detecting a single marker is insufficient. Here, we introduce an optical biosensor based on a nanopillar structure that employs a gold nanoparticle amplification strategy. The sensor is able to detect 20 pg/ml of A$β$42 and A$β$40 in undiluted serum, which is the clinically required level. We also show the detection of the A$β$42 and A$β$40 peptides in the same channel, which is highly relevant for assessing disease progress and opens a route towards multiplexing. Alongside their simplicity and portability, these nanotechnology innovations make a major contribution to the ability to detect and monitor the progression of neurodegenerative diseases such as Alzheimer's.